HopeStage
Back to all studies
CompletedNCT01955564

A Phase I- Sequential Cohort Dosing to Determine Maximum Tolerated Dose in Healthy Male Volunteers.

Medication studyAges 18–45United StatesSchizophrenia
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 45 years.

Listed locations
Long BeachSee all locations and recruitment
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateJune 2013
Recruitment status
Completed
Enrollment listed in the registry
54
Sponsor
Newron Pharmaceuticals SPA
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Locations
United States
Age range
From 18 Years to 45 Years
Official registry ID
NCT01955564
Official title
Show the full official title

A Phase I, Prospective, Randomized, Double-blind, Placebo-controlled, Sequential-cohort, Escalating, Single-dose Study Designed to Determine the Maximum Tolerated Oral Dose of NW-3509A in Healthy, Male Volunteers.

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Long Beach

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Newron Pharmaceuticals SPA.

Did this study involve medication?

Yes. The study involved medication, including NW-3509a.

Who was this study for?

Listed age limits: 18 years to 45 years.

Want to explore more studies?

Explore studies